0000000000991826

AUTHOR

M. De Rosa

showing 5 related works from this author

Surgeons' fear of getting infected by COVID19: A global survey

2020

During the last three months, COVID- 19 pandemic had led to a serious backlog of operations globally, and plans for restarting operation are imperative. Recommendations for surgical activities were studied, aiming to protect the surgical staff from being infected. In the meantime, it is also important to give attention to the surgeon’s personal feeling during work. We conducted a survey to investigate global surgi- cal practices during the COVID-19 pandemic, and the surgeon’s personal feeling was also investigated in the sur- vey. In this special letter, we performed multivariate analysis to explore factors that associated with surgeon’s fear of getting infected by COVID-19.

Surgery COVID-19medicine.medical_specialty2019-20 coronavirus outbreakInfectious Disease Transmission Patient-to-Professionalsurvey covid19Coronavirus disease 2019 (COVID-19)Attitude of Health PersonnelSettore MED/18 - CHIRURGIA GENERALESevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Infectious Disease TransmissionCOVID-19. Global surgery.MEDLINEGlobal HealthNOPatient-to-ProfessionalTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]Surveys and QuestionnairesCorrespondencemedicineGlobal healthInfection controlHumansGeneralPersonal protective equipmentPersonal Protective EquipmentLS7_4SurgeonsInfection Controlcovid-19; pandemic; surgerySARS-CoV-2business.industrypandemicVaccinationCOVID-19covidFearSettore MED/18Occupational DiseasesCOVID-19; Global Health; Humans; Infection Control; Occupational Diseases; Personal Protective Equipment; Surgeons; Surveys and Questionnaires; Attitude of Health Personnel; Fear; Infectious Disease Transmission Patient-to-ProfessionalSurgeon - infection - COVID19 - surveyFamily medicineSurgerybusiness
researchProduct

Three years of experience : the Italian registry and safety data update

2011

At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February 2010, almost 3,000 cases have been treated with natalizumab. The drop-out rate is 10%. Almost 800 cases received cycles of natalizumab for more than 18 months. One case of PML was reported and other adverse events are similar to those described in phase III studies. The majority of cases remained stable, while in 25% of cases, an improvement of disability…

AdultMalemedicine.medical_specialtyPediatricsMultiple SclerosisDermatologyDiseaseAntibodies Monoclonal HumanizedNatalizumabPharmacovigilanceProduct Surveillance PostmarketingmedicineHumansRegistriesAdverse effectbusiness.industryNatalizumabMultiple sclerosisGeneral Medicinemedicine.diseasePsychiatry and Mental healthItalyPHARMACOVIGILANCEREGISTRYsurveillance program; pharmacovigilance; multiple sclerosis; natalizumabPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)NeurosurgerybusinessMultiple sclerosis NatalizumabSurveillance program Pharmacovigilancemedicine.drug
researchProduct

The critical view of safety during laparoscopic cholecystectomy: Strasberg Yes or No? An Italian Multicentre study

2020

Abstract Background Laparoscopic cholecystectomy is considered the gold standard for the treatment of gallbladder lithiasis; nevertheless, the incidence of bile duct injuries (BDI) is still high (0.3–0.8%) compared to open cholecystectomy (0.2%). In 1995, Strasberg introduced the "Critical View of Safety" (CVS) to reduce the risk of BDI. Despite its widespread use, the scientific evidence supporting this technique to prevent BDI is controversial. Methods Between March 2017 and March 2019, the data of patients submitted to laparoscopic cholecystectomy in 30 Italian surgical departments were collected on a national database. A survey was submitted to all members of Italian Digestive Pathology…

medicine.medical_specialtyCritical view of safetymedicine.medical_treatmentLaparoscopic trainingbBile duct injuriesBile duct injuries; Cholecystectomy; Critical view of safety; Intraoperative bleeding; Laparoscopic training; LaparoscopyBile Duct DiseasesArticlebBile duct injuries; cholecystectomy; critical view of safety; intraoperative bleeding; laparoscopic training; laparoscopyMedicineHumansCholecystectomyLaparoscopyIntraoperative ComplicationsIntraoperative bleedingmedicine.diagnostic_testbusiness.industryBile ductGeneral surgeryGallbladderIncidence (epidemiology)Gold standardGallbladderPerioperativeBile duct injuriesmedicine.anatomical_structureCholecystectomy LaparoscopicItalySurgeryCholecystectomyLaparoscopyBile DuctsbusinessBile duct injurieAbdominal surgery
researchProduct

Impact of asymptomatic COVID-19 patients in global surgical practice during the COVID-19 pandemic

2020

The rapid spread of COVID-19 has changed the global surgical care. Patients infected with COVID-19 may present without typical symptoms, and such asymptomatic patients may potentially trigger in-hospital outbreaks by transmitting the disease to health care providers and other hospitalized patients. Further, asymptomatic COVID-19 patients have worse postop- erative outcomes with an unexpectedly high morbidity and mortality, reaching 20⋅5 per cent deaths. However, we do not have objective global data on this issue. In an attempt to clarify the current global surgical practice under the COVID-19 pandemic particularly focusing on the preoperative screening of asymptomatic COVID-19 patients, we …

2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)covid-19 pandemic surgerySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Settore MED/18 - CHIRURGIA GENERALEMEDLINECOVID-19. Global surgery.AsymptomaticCOVID-19 Critical Pathways Cross Infection Cross-Sectional Studies Health Care Surveys Humans Pandemics Postoperative Complications SARS-CoV-2 Surgical Procedures Operative Asymptomatic InfectionsCOVID-19; Critical Pathways; Cross Infection; Cross-Sectional Studies; Health Care Surveys; Humans; Pandemics; Postoperative Complications; SARS-CoV-2; Surgical Procedures Operative; Asymptomatic InfectionsNOsurgeryTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]Postoperative ComplicationsPandemicCorrespondencemedicineHumansPandemicsAsymptomatic InfectionsLS7_4COVIDCross InfectionSurgical ProceduresCritical pathwaysbusiness.industrySARS-CoV-2pandemicCOVID-19Surgical proceduresOperativeSettore MED/18covid 19 surgical practiceCOVID-19 - surgeryCross-Sectional StudiesSurgical Procedures OperativeHealth Care SurveysEmergency medicineCritical Pathwaysmedicine.symptombusiness
researchProduct

The pharmacovigilance program on natalizumab in Italy: 2 years of experience.

2009

At the end of 2006 a country-based surveillance program on natalizumab therapy in multiple sclerosis was settled in Italy by a collaborative effort of the Italian Drug Agency (AIFA) and a group of experts and neurologists appointed by the National Society of Neurology (SIN). After 2 years, 1,818 patients are registered in the database. The majority of cases (88.6%) failed the therapy with beta interferon or glatiramer acetate and had relapses or accumulated disability during immunomodulating treatment, while 11.4% of patients enrolled in the surveillance study were not previously treated with immunomodulating therapies and had a rapidly evolving clinical course. Almost 10% of the patients t…

AdultMalemedicine.medical_specialtyPediatricsNeurologyMultiple SclerosisPatient DropoutsDatabases FactualAlternative medicineDermatologyPharmacologyAntibodies Monoclonal HumanizedNatalizumabPharmacovigilanceProduct Surveillance PostmarketingMedicineHumansGlatiramer acetateMultiple sclerosis NatalizumabSurveillance programPharmacovigilancebusiness.industryMultiple sclerosisNatalizumabAntibodies MonoclonalDrug agencyGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingPsychiatry and Mental healthItalyPHARMACOVIGILANCEREGISTRYSettore MED/26 - NeurologiaFemaleNeurology (clinical)Neurosurgerybusinessmedicine.drugFollow-Up StudiesNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct